Shenzhen Xzing Technology Co.,Ltd. – Trademark Portfolio
Entity Type: 99
Shenzhen Xzing Technology Co.,Ltd. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 4 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 2 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include SWI, GALENUS, ENDOFRESH, and E ENDOFRESH MED-TECH AND BEYOND. The owner is based in Nanshan Dist, Shenzhen.
Rm 1101,A bldg,Huazhong University of
Nanshan Dist, Shenzhen 518000 , CN
Showing of trademarks Trademarks
Trademark Classifications
Shenzhen Xzing Technology Co.,Ltd.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does Shenzhen Xzing Technology Co.,Ltd. have?
Shenzhen Xzing Technology Co.,Ltd. has 4 U.S. trademarks filed with the USPTO. Of these, 4 registered.
What trademark classes does Shenzhen Xzing Technology Co.,Ltd. file in?
Shenzhen Xzing Technology Co.,Ltd. files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 35 (Advertising & Business). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are Shenzhen Xzing Technology Co.,Ltd.'s most well-known trademarks?
Shenzhen Xzing Technology Co.,Ltd.'s registered trademark portfolio includes well-known marks such as SWI, GALENUS, ENDOFRESH, and E ENDOFRESH MED-TECH AND BEYOND. These are among 4 currently registered trademarks in the portfolio.
What is Shenzhen Xzing Technology Co.,Ltd.'s trademark registration success rate?
Shenzhen Xzing Technology Co.,Ltd. has a 100% trademark registration rate, with 4 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.